Adage Capital Partners
CERE

Adage Capital Partners’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Adage Capital Partners’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-609,765
Closed -$24.9M – 961
2024
Q2 		$24.9M Buy
609,765
+27,131
+5% +$1.13M 0.05% 382
2024
Q1 		$24.6M Sell
582,634
-36,572
-6% -$1.54M 0.05% 395
2023
Q4 		$26.3M Sell
619,206
-886,770
-59% -$25.5M 0.05% 347
2023
Q3 		$32.9M Buy
1,505,976
+755,976
+101% +$18.9M 0.07% 273
2023
Q2 		$23.8M Buy
750,000
+351,480
+88% +$10.8M 0.05% 360
2023
Q1 		$9.72M Hold
398,520
– – 0.02% 623
2022
Q4 		$12.6M Hold
398,520
– – 0.03% 573
2022
Q3 		$11.3M Buy
398,520
+78,520
+25% +$2.34M 0.03% 607
2022
Q2 		$8.46M Sell
320,000
-80,000
-20% -$2.27M 0.02% 710
2022
Q1 		$14M Buy
400,000
+90,000
+29% +$2.63M 0.03% 600
2021
Q4 		$10.1M Buy
310,000
+60,000
+24% +$2.12M 0.02% 692
2021
Q3 		$7.38M Sell
250,000
-250,000
-50% -$7.02M 0.01% 776
2021
Q2 		$12.8M Sell
500,000
-100,000
-17% -$1.43M 0.03% 625
2021
Q1 		$8.24M Hold
600,000
– – 0.02% 729
2020
Q4 		$9.95M Buy
600,000
+300,000
+100% +$3.9M 0.02% 593
2020
Q3 		$3.13M Buy
+300,000
New +$3.17M 0.01% 684

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Adage Capital Partners's CERE Position: Q3 2024 in Review

Adage Capital Partners sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 609,765 shares — an estimated $24.9M sold.

Adage Capital Partners first reported a position in CERE in Q3 2020 and held it in 16 quarters. The position peaked at $32.9M in Q3 2023. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Adage Capital Partners reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Adage Capital Partners sold 609,765 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $24.9M.
  • Adage Capital Partners first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2020 and held it in 16 quarters.
  • Adage Capital Partners's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $32.9M in Q3 2023.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Adage Capital Partners's 13F filing for Q3 2024, filed 14 Nov 2024.